Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMB-01 Plus Osimertinib in Advanced EGFR-mutant NSCLC
NCT05498389Phase 2Unknown
- Sponsor
- EpimAb Biotherapeutics
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of emb-01 in non-small cell lung cancer (NSCLC), sponsored by EpimAb Biotherapeutics. Status: unknown.
02
Drugs
emb-01
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05498389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05498389.